The purpose of this study is to determine whether nerve growth factor (cerebrolysin®) therapy will improve the psychomotor outcome in infants with moderate and severe hypoxic ischemic encephalopathy after hospital discharge.
Infants with perinatal history of moderate to severe Hypoxic ischemic encephalopathy HIE will receive 10 injections of cerebrolysin IM. Assessment of neurodevelopment will be done before , 3 and 6 months after therapy
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
PREVENTION
Masking
NONE
Enrollment
40
injection of cerebrolysin® 0.1ml/kg IM twice weekly for 10 injections after discharge from NICU (postneonatal)
Children's Hospital, Faculty of Medicine, Ain Shams University
Cairo, Cairo Governorate, Egypt
Children's Hospital, Faculty of Medicine, Ain Shams University
Cairo, Egypt
Side effects during cerebrolysin therapy (one course).
weekly physical , neurological examination and parents' reported fever or convulsion during cerebrolysin injection course (10 injections).
Time frame: 3 months
Neurodevelopmental follow up after 6 and 9 months of cerebrolysin injection.
Time frame: 9 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.